Clinical Trials Logo
  1. Home
  2. Type2 Diabetes Mellitus
  3. NCT03847116

Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease

Type2 Diabetes Mellitus Clinical Trial

Official title:
Association of Light-to-moderate Alcohol Consumption With Risk of Type 2 Diabetes Mellitus in Individuals With Nonalcoholic Fatty Liver Disease

Clinical Trial Summary

This study explored the cross-sectional and prospective associations between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03847116
Study type Observational
Source Ningbo No. 1 Hospital
Contact
Status Completed
Phase
Start date January 1, 2009
Completion date February 10, 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A